Direct cell engineering reshapes cancer therapy

Californian researchers have demonstrated a new method to generate cancer-fighting immune cells directly inside the human body, potentially transforming one of the most complex and costly treatments for blood cancers. The approach, detailed in a peer-reviewed study, aims to bypass the elaborate laboratory process required for conventional CAR-T therapy, offering the prospect of faster, more accessible treatment.

Chimeric antigen receptor T-cell therapy, widely known as CAR-T, has been hailed as a breakthrough for conditions such as leukaemia and lymphoma. The standard procedure involves extracting a patient’s T cells, genetically modifying them in specialised facilities to recognise cancer cells, and reinfusing them into the bloodstream. While effective, the process can take weeks, involves significant expense, and is limited to a small number of advanced centres.

The Californian team has developed a technique that instead delivers genetic instructions directly into the patient’s body, effectively reprogramming T cells in situ. Using engineered viral vectors or nanoparticle-based systems, the therapy targets immune cells and equips them with the ability to identify and attack cancerous cells without the need for external manipulation.

Early-stage data from laboratory and animal studies suggest that the method can generate functional CAR-T cells within days. Researchers say this could reduce treatment delays that often prove critical for patients with aggressive cancers. “The goal is to make this therapy as straightforward as administering a conventional drug,” one of the study’s lead scientists noted, highlighting the ambition to move from bespoke manufacturing to scalable medicine.

The findings arrive amid sustained efforts across the biotechnology sector to simplify cell therapies. Companies and academic groups have been exploring in vivo gene delivery for several years, though challenges around safety, precision targeting and immune reactions have slowed progress. The latest study claims improvements in delivery accuracy, ensuring that genetic material is largely confined to T cells while minimising off-target effects.

Safety remains a central concern. CAR-T therapies, even in their current form, can trigger severe side effects such as cytokine release syndrome and neurological complications. Experts caution that introducing gene-editing components directly into the body raises additional risks, including unintended immune responses or long-term genetic alterations. Regulatory scrutiny is expected to intensify as such approaches move closer to human trials.

Despite these concerns, the potential benefits are drawing attention from clinicians and investors alike. Conventional CAR-T treatments can cost hundreds of thousands of dollars per patient, reflecting the bespoke nature of the therapy. By eliminating the need for cell extraction and laboratory engineering, in vivo approaches could significantly reduce costs and expand availability beyond specialised centres in North America, Europe and parts of Asia.

Oncologists note that broader access could be particularly significant for low- and middle-income regions, where infrastructure for advanced cell therapies remains limited. “If this approach proves safe and effective in humans, it could democratise access to one of the most powerful cancer treatments available,” a senior haematologist said, while cautioning that clinical validation will take time.

The study also underscores a broader shift in cancer research towards precision immunotherapy. Advances in gene editing, including CRISPR-based technologies, have enabled scientists to design increasingly targeted interventions. At the same time, improvements in delivery systems—ranging from viral vectors to lipid nanoparticles—have opened new pathways for administering genetic material safely within the body.

Industry analysts view the development as part of a competitive landscape where pharmaceutical companies are racing to refine next-generation cell therapies. Several firms are already testing off-the-shelf CAR-T products derived from donor cells, aiming to reduce costs and waiting times. The in vivo approach could represent a further step, potentially eliminating manufacturing bottlenecks altogether.

Clinical trials will determine whether the promise translates into real-world outcomes. Researchers are preparing to test the therapy in human patients, focusing initially on specific blood cancers where CAR-T has already shown efficacy. These trials will assess not only the treatment’s effectiveness but also its safety profile, dosage requirements and durability of response.

Regulators are likely to proceed cautiously, given the novelty of administering gene-modifying therapies directly into patients. Previous experiences with gene therapy have shown both transformative success and unforeseen complications, underscoring the need for rigorous oversight. Long-term monitoring will be essential to understand any delayed effects.

Patients’ groups have responded with cautious optimism, recognising the potential to simplify treatment while emphasising the importance of transparency and safety. For many individuals facing advanced blood cancers, delays in accessing CAR-T therapy can be life-threatening, making faster alternatives particularly appealing.